Edition:
United States

Xenon Pharmaceuticals Inc (XENE.OQ)

XENE.OQ on NASDAQ Stock Exchange Global Market

5.35USD
4:00pm EDT
Change (% chg)

$-0.05 (-0.93%)
Prev Close
$5.40
Open
$5.35
Day's High
$5.35
Day's Low
$5.30
Volume
2,658
Avg. Vol
11,514
52-wk High
$5.75
52-wk Low
$2.15

Latest Key Developments (Source: Significant Developments)

Xenon Pharma, Teva Pharma Terminate Development & License Agreement
Wednesday, 7 Mar 2018 04:01pm EST 

March 7 (Reuters) - Xenon Pharmaceuticals Inc ::XENON PHARMACEUTICALS REPORTS 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.XENON PHARMA - CO, TEVA PHARMACEUTICALS INTERNATIONAL GMBH, TEVA CANADA, ENTERED DEAL TO MUTUALLY TERMINATE DEC 7, 2012 DEVELOPMENT & LICENSE AGREEMENT.XENON PHARMA - AS PER TERMINATION AGREEMENT, TEVA AGREED TO TRANSFER AND ASSIGN 1 MILLION SHARES OF CO HELD BY TEVA CANADA LTD TO CO FOR CANCELLATION.  Full Article

Xenon Pharmaceuticals Expects To Have Ongoing XEN1101 Phase 1 Clinical Trial Completed By Mid-Year
Monday, 8 Jan 2018 08:30am EST 

Jan 8 (Reuters) - Xenon Pharmaceuticals Inc ::XENON PHARMACEUTICALS OUTLINES KEY MILESTONES FOR 2018.XENON PHARMACEUTICALS INC - EXPECT TO HAVE ONGOING XEN1101 PHASE 1 CLINICAL TRIAL COMPLETED BY MID-YEAR.XENON PHARMACEUTICALS INC - IN SECOND HALF OF THIS YEAR, ANTICIPATE HAVING COMPLETED XEN901 PHASE 1 CLINICAL TRIAL.XENON PHARMACEUTICALS INC - ANTICIPATE THAT BOTH XEN1101 AND XEN901 COULD BE IN PHASE 2 DEVELOPMENT BY END OF THIS YEAR.XENON PHARMACEUTICALS INC - AS OF DECEMBER 31, 2017, CASH AND CASH EQUIVALENTS AND MARKETABLE SECURITIES WERE $43.7 MILLION.XENON PHARMACEUTICALS INC - BASED ON CURRENT ASSUMPTIONS, XENON ANTICIPATES HAVING SUFFICIENT CASH TO FUND OPERATIONS INTO MID-2019.  Full Article

Xenon Pharma Says Entered Into Loan And Security Agreement With Silicon Valley Bank
Monday, 18 Dec 2017 04:17pm EST 

Dec 18 (Reuters) - Xenon Pharmaceuticals Inc ::XENON PHARMACEUTICALS- ON DEC 18, CO, UNIT ENTERED INTO LOAN AND SECURITY AGREEMENT WITH SILICON VALLEY BANK - SEC FILING.XENON PHARMACEUTICALS - PURSUANT TO AGREEMENT, BANK AGREED TO EXTEND TERM LOANS TO CO WITH AGGREGATE PRINCIPAL AMOUNT OF UP TO $15 MILLION.XENON PHARMACEUTICALS INC - BORROWINGS UNDER LOAN AGREEMENT WILL CONSIST OF UP TO THREE SEPARATE TRANCHES.  Full Article

Xenon Pharmaceuticals reports Q3 loss per share $0.43
Tuesday, 7 Nov 2017 04:57pm EST 

Nov 7 (Reuters) - Xenon Pharmaceuticals Inc :Xenon Pharmaceuticals reports third quarter 2017 financial results and provides corporate update.Q3 revenue $300,000 versus $400,000.Xenon Pharmaceuticals Inc - qtrly loss per share $0.43.  Full Article

Xenon Pharma announces initiation of XEN1101 phase 1 clinical trial
Tuesday, 17 Oct 2017 08:30am EDT 

Oct 17 (Reuters) - Xenon Pharmaceuticals Inc :Xenon Pharmaceuticals announces initiation of XEN1101 phase 1 clinical trial.XEN1101 phase 2 proof-of-concept clinical trial anticipated to begin in Q3 2018​.Expect to file an IND equivalent application in Q4 of this year for XEN901​.  Full Article

Xenon Pharmaceuticals Q2 net loss per common share $0.41​
Thursday, 3 Aug 2017 04:02pm EDT 

Aug 3 (Reuters) - Xenon Pharmaceuticals Inc ::Xenon Pharmaceuticals reports second quarter 2017 financial results and provides corporate update.Xenon Pharmaceuticals Inc - ‍qtrly net loss per common share $0.41​.Xenon - ‍cash and cash equivalents and marketable securities as of June 30, 2017 were $51.7 million, compared to $64.1 million as of December 31, 2016​.  Full Article

Xenon Pharmaceuticals reports qtrly loss per share $0.43
Tuesday, 9 May 2017 04:03pm EDT 

May 9 (Reuters) - Xenon Pharmaceuticals Inc :Xenon Pharmaceuticals reports first quarter 2017 financial results and provides corporate update.Xenon Pharmaceuticals - For quarter ended March 31, 2017, Xenon reported total revenue of $0.02 million, compared to $0.6 million for same period in 2016.Qtrly loss per share $0.43.  Full Article

Xenon acquires potassium channel modulator epilepsy treatment
Wednesday, 26 Apr 2017 06:30am EDT 

April 26 (Reuters) - Xenon Pharmaceuticals Inc ::Xenon Pharmaceuticals inc says phase 2 proof-of-concept clinical trial beginning in mid-2018.Xenon expands ion channel neurology pipeline with acquisition of new potassium channel modulator for the treatment of epilepsy.Xenon Pharmaceuticals Inc - Xenon anticipates filing an IND, or IND equivalent, to initiate a phase 1 first-in-man clinical trial in Q4 of 2017.Xenon Pharmaceuticals inc says anticipates filing an IND, or IND equivalent, to initiate a phase 1 first-in-man clinical trial in q4 of 2017.  Full Article

Xenon Pharma says XEN801 did not meet endpoints in mid-stage study
Friday, 24 Mar 2017 06:30am EDT 

Xenon Pharmaceuticals Inc : Xenon Pharmaceuticals announces XEN801 did not meet efficacy endpoints in phase 2 clinical trial in patients with moderate to severe acne . Xenon Pharmaceuticals announces XEN801 did not meet efficacy endpoints in phase 2 clinical trial in patients with moderate to severe acne . Xenon Pharmaceuticals Inc - XEN801 did demonstrate a favorable safety and tolerability profile, with no drug-related serious adverse events .Xenon Pharmaceuticals Inc - results also show that xen801 did not demonstrate statistical significance relative to key secondary efficacy endpoints.  Full Article

Xenon Pharma FY 2016 net loss $23 mln
Wednesday, 8 Mar 2017 04:01pm EST 

Xenon Pharmaceuticals Inc : Xenon Pharmaceuticals reports 2016 financial results and provides corporate update .Xenon Pharmaceuticals Inc - net loss for year ended December 31, 2016 was $23.0 million, compared to $15.8 million for same period in 2015.  Full Article

BRIEF-Xenon Pharma, Teva Pharma Terminate Development & License Agreement

* XENON PHARMACEUTICALS REPORTS 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE